Shrinking height in older adults is due to ageing. It could mean serious spinal fractures caused by bone loss over time.

The global kyphoplasty market size was US$ 632.45 million in 2021. The global kyphoplasty market size is forecast to reach US$ 1086.7 million by 2030, growing at a compound annual growth rate (CAGR) ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

The 65-year-old, of Altham, east Lancashire, had suffered a fractured vertebrae following a fall. She sadly died in hospital ...

Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of ...

After her death Carol's friend Nichola Jones posted online: "Carol you were a legend and you are going to be missed. Over the ...

Biocon said that Biocon Biologics has received marketing authorisations from UK Medicines and Healthcare products Regulatory Agency for Vevzuo and Evfraxy, biosimilars of Denosumab.

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...